Business
Vesting of Awards under Long Term Incentive Plan
Vesting of Awards under Long Term Incentive Plan.
About this update from Allergy Therapeutics Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 0997U\n Allergy Therapeutics PLC\n 31 March 2021\n \n \n \n \n \n \n \n \n \n \n Allergy Therapeutics plc\n \n \n (\"Allergy Therapeutics\" or the \"Group\")\n \n \n \n \n \n Vesting of Awards under Long Term Incentive Plan, \n \n \n \n \n \n Increase to Block Listing\n \n \n \n \n \n and\n \n \n \n \n \n Total Voting Rights\n \n \n \n \n \n Allergy Therapeutics (AIM:AGY), the fully integrated pharmaceutical company specialising in allergy vaccines, announces that\n :\n \n \n \n \n \n Vesting of Award\n \n \n Performance conditions attaching to provisional awards (\"Awards\") made pursuant to the Company's Long Term Incentive Plan (\"LTIP\") for the three years ended 15 March 2021, details of which were announced on 16 March 2018, have been met in part.\n \n \n Consequently, on 30 March 2021, Allergy Therapeutics granted certain of its director's options (\"Options\") over the Company's Ordinary Shares in replacement for the Awards made under the LTIP as follows:\n \n \n \n \n \n Director\n \n \n \n \n Percentage of Award Vested\n \n \n \n \n Total number of Ordinary Shares over which Options granted\n \n \n \n \n Exercise Price\n \n \n \n \n \n \n M\n anuel Llobet\n \n \n \n \n 50%\n \n \n \n \n 450,000\n \n \n \n \n 0.1 pence\n \n \n \n \n \n \n Nicolas Wykeman\n \n \n \n \n 50%\n \n \n \n \n 225,000\n \n \n \n \n 0.1 pence\n \n \n \n \n \n \n \n \n In accordance with the rules of the LTIP, \n 50% of these Options are exercisable immediately and the remaining 50% are subject to a holding period of three years. The exercise period is ten years from date of grant. \n \n \n Following the above share transactions, the Executive Directors hold the following:\n \n \n \n \n \n Director\n \n \n \n \n Unvested LTIP Awards\n \n \n \n \n Options\n \n \n \n \n Interest in Ordinary Shares\n \n \n \n \n \n \n Manuel Llobet\n \n \n \n \n 2,700,000\n \n \n \n \n 872,500\n \n \n \n \n 3,325,000\n \n \n \n \n \n \n Nicolas Wykeman\n \n \n \n \n 1,350,000\n \n \n \n \n 436,250\n \n \n \n \n 300,000\n \n \n \n \n \n \n \n \n \n \n \n Increase to Block Listing\n \n \n \n \n \n Allergy Therapeutics announces that application has been made for admission to trading on AIM in respect of an additional block listing of 7,000,000 ...